CN107002138B - 用于评估发展乳腺癌风险的方法 - Google Patents

用于评估发展乳腺癌风险的方法 Download PDF

Info

Publication number
CN107002138B
CN107002138B CN201580063966.2A CN201580063966A CN107002138B CN 107002138 B CN107002138 B CN 107002138B CN 201580063966 A CN201580063966 A CN 201580063966A CN 107002138 B CN107002138 B CN 107002138B
Authority
CN
China
Prior art keywords
risk
breast cancer
single nucleotide
snp
risk assessment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580063966.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107002138A (zh
Inventor
理查德·奥尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Technologies Ltd
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of CN107002138A publication Critical patent/CN107002138A/zh
Application granted granted Critical
Publication of CN107002138B publication Critical patent/CN107002138B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
CN201580063966.2A 2014-09-30 2015-09-29 用于评估发展乳腺癌风险的方法 Expired - Fee Related CN107002138B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903898 2014-09-30
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (2)

Publication Number Publication Date
CN107002138A CN107002138A (zh) 2017-08-01
CN107002138B true CN107002138B (zh) 2022-06-14

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063966.2A Expired - Fee Related CN107002138B (zh) 2014-09-30 2015-09-29 用于评估发展乳腺癌风险的方法

Country Status (11)

Country Link
US (2) US10920279B2 (enExample)
EP (1) EP3201360A4 (enExample)
JP (1) JP6820838B2 (enExample)
KR (1) KR102334702B1 (enExample)
CN (1) CN107002138B (enExample)
AU (2) AU2015327756B2 (enExample)
CA (1) CA2962691C (enExample)
IL (1) IL251376B (enExample)
MX (1) MX392267B (enExample)
SG (1) SG11201702416YA (enExample)
WO (1) WO2016049694A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468901B1 (en) 2005-11-29 2017-04-05 Cambridge Enterprise Limited Markers for breast cancer
DK2438193T3 (en) 2009-06-01 2015-10-19 Genetic Technologies Ltd Methods for assessing the risk of breast cancer
CA2962691C (en) 2014-09-30 2023-05-23 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20200102617A1 (en) * 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US12577622B2 (en) 2017-06-02 2026-03-17 Myriad Genetics, Inc. Detecting cancer risk
CA3078756A1 (en) * 2017-10-13 2019-04-18 Genetic Technologies Limited Methods of assessing risk of developing breast cancer
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克（北京）生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
KR20230019872A (ko) * 2020-05-27 2023-02-09 지네틱 테크놀로지스 리미티드 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN114283883B (zh) * 2021-12-27 2022-11-22 上海华测艾普医学检验所有限公司 基于分子标记的用于肝癌筛查和风险预测的系统及应用
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
CN102575289A (zh) * 2009-06-25 2012-07-11 耶鲁大学 在处的单核苷酸多态性和癌症风险
CN102712949A (zh) * 2009-06-01 2012-10-03 遗传技术有限公司 用于乳腺癌风险评估的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｐｃｒ中のハイブリダイゼーションのモニタリング
AU723400B2 (en) 1996-11-07 2000-08-24 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
MXPA01005513A (es) 1998-12-02 2003-07-14 Dna Sciences Inc Metodos para reducir la variacion en estudios de tratamiento utilizando genotipificacion.
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
EP1305446A4 (en) 2000-07-25 2004-10-06 Dz Genes Llc DIAGNOSIS OF ECNOS PROMOTER POLYMORPHISMS
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
EP2135960A1 (en) 2001-09-19 2009-12-23 Intergenetics Incorporated Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
WO2005024067A2 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
EP2468901B1 (en) 2005-11-29 2017-04-05 Cambridge Enterprise Limited Markers for breast cancer
CA2656199A1 (en) 2006-06-23 2007-12-27 Intergenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
EP2137324A2 (en) 2007-03-26 2009-12-30 Decode Genetics EHF Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
JP2010527603A (ja) 2007-05-25 2010-08-19 ディコーデ ジェネテクス イーエイチエフ 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異
CA2693783A1 (en) 2007-07-11 2009-01-15 Intergenetics, Inc. Genetic models for stratification of cancer risk
KR20110053995A (ko) 2008-08-08 2011-05-24 네이비제닉스 인크. 개인별 활동 계획을 위한 방법 및 체계
GB2477868A (en) 2008-09-12 2011-08-17 Navigenics Inc Methods and systems for incorporating multiple environmental and genetic risk factors
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
CA2962691C (en) 2014-09-30 2023-05-23 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20200102617A1 (en) 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
CA3078756A1 (en) 2017-10-13 2019-04-18 Genetic Technologies Limited Methods of assessing risk of developing breast cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
CN102712949A (zh) * 2009-06-01 2012-10-03 遗传技术有限公司 用于乳腺癌风险评估的方法
CN102575289A (zh) * 2009-06-25 2012-07-11 耶鲁大学 在处的单核苷酸多态性和癌症风险

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement;Hatef Darabi;《Breast Cancer》;20121231;第14卷(第1期);第1-11页 *
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women;McCarthy;《Breast Cancer Research And Treatment》;20130430;第138卷(第3期);第889-898页 *
Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model;Gillian S Dite;《Breast Cancer Research And Treatment》;20130630;第139卷(第3期);第887-896页 *
乳腺癌易感基因单核苷酸多态性与个体化预防;杨学习;《中国妇幼保健》;20121231;第27卷(第24期);第3834-3835页 *

Also Published As

Publication number Publication date
CN107002138A (zh) 2017-08-01
AU2018202299A1 (en) 2018-04-26
AU2015327756A1 (en) 2017-04-13
US10683549B2 (en) 2020-06-16
US20180305764A1 (en) 2018-10-25
EP3201360A1 (en) 2017-08-09
MX2017004127A (es) 2017-10-24
IL251376B (en) 2022-09-01
AU2018202299B9 (en) 2020-03-05
US10920279B2 (en) 2021-02-16
EP3201360A4 (en) 2018-05-09
CA2962691A1 (en) 2016-04-07
WO2016049694A1 (en) 2016-04-07
IL251376A0 (en) 2017-05-29
JP2017529859A (ja) 2017-10-12
AU2015327756B2 (en) 2018-01-04
KR20170063977A (ko) 2017-06-08
SG11201702416YA (en) 2017-04-27
US20160222469A1 (en) 2016-08-04
MX392267B (es) 2025-03-24
CA2962691C (en) 2023-05-23
JP6820838B2 (ja) 2021-01-27
AU2018202299B2 (en) 2019-10-24
KR102334702B1 (ko) 2021-12-06

Similar Documents

Publication Publication Date Title
CN107002138B (zh) 用于评估发展乳腺癌风险的方法
JP7126704B2 (ja) 結腸直腸癌発症のリスクを評価するための方法
US20200102617A1 (en) Improved Methods For Assessing Risk of Developing Breast Cancer
AU2022279367A1 (en) Methods of assessing risk of developing breast cancer
EP4445388A1 (en) Breast cancer risk assessment
HK40001097B (en) Methods for assessing risk of developing colorectal cancer
HK40001097A (en) Methods for assessing risk of developing colorectal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220614

CF01 Termination of patent right due to non-payment of annual fee